Research programme: monoclonal antibody immunoconjugates - Valor Biotherapeutics
Alternative Names: CmAbs; IGN 001; IGN 003; mAb-IFN fusion protein therapeutics - Valor Biotherapeutics; mAb-IFN therapeutics - ImmunGene/Valor Biotherapeutics; Monoclonal antibody fusion proteins - ImmunGene/Caliber Biotherapeutics/Valor BiotherapeuticsLatest Information Update: 28 Jun 2021
At a glance
- Originator ImmunGene
- Developer Valor Biotherapeutics
- Class Immunoconjugates; Monoclonal antibodies; Proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Cancer; Multiple myeloma
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral)
- 28 Jun 2021 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (Parenteral)
- 28 Aug 2020 No recent reports of development identified for research development in Cancer in USA (Parenteral)